Oncology

Adoptive transfer of TILs elicited an ORR of 56% in patients with metastatic melanoma who were naïve to PD-1 inhibitors compared with 24% in patients refractory to PD-1 inhibitors.

Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s CAR T Engager protein technology.

Six of 7 mice treated with a new, higher dose of BMN-307 showed tumors in liver necropsy at 52 weeks post-treatment.

The hematologist/oncologist at the Harold C. Simmons Comprehensive Cancer Center discussed the rationale behind using CAR T-cell therapy in relapsed/refractory multiple myeloma and data from the KarMMa trial.

Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed cell therapy for multiple myeloma and COVID-19 respiratory distress.

Experts discussed novel options such as CAR T-cell therapy for optimizing treatment in MCL, myelofibrosis, and ALL.

Experts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.

The investigational cell therapy consists of T-cell receptor (TCR) fusion construct T cells (TRuC-T cells).

The FDA has cleared a batch of VB-111 manufactured in Modiin, Israel, following a technical review.

Experts discuss emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.

A post-hoc analysis overviewed long-term efficacy of autologous hematopoietic stem cell transplantation in mantle cell lymphoma.

The hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.

The early-phase data readout follows news that the FDA recently approved its IND for its CAR-T candidate in multiple myeloma.

Experts discussed treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.

The associate professor from The University of Texas MD Anderson Cancer Center discussed future research with CAR T therapy in multiple myeloma.

Patients with MDS treated with alloHSCT and 5-aza had significant improvements in event-free survival compared to 5-aza treatment alone.

Experts discussed data from trials in lymphoma presented at ASCO 2021.

The chief of Oncology and Hematology at University of Nebraska Medical Center, discussed the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma (NHL) paradigm.

The 4-day virtual conference will feature plenary presentations, workshops, and bootcamps led by cell therapy industry leaders with expertise in discovery, development, manufacturing, and more.

The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.

The CAR T therapy tisagenlecleucel missed its EFS endpoint in the phase 3 BELINDA trial for B-cell non-Hodgkin lymphoma.

The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Stephen M. Ansell, MD, PhD, discussed the potential of using non–CAR T-based novel approaches in the non-Hodgkin lymphoma treatment paradigm.

FT516 and FT595 are both currently being evaluated in phase 1 trials for B-cell malignancies.

KITE-363 is set to be investigated in a phase 1 clinical trial at the end of 2021.